25
Participants
Start Date
October 19, 2020
Primary Completion Date
June 15, 2022
Study Completion Date
June 30, 2022
M7824
Participants received bintrafusp alfa until confirmed disease progression, death, unacceptable toxicity and study withdrawal maximum of 2 years (at the discretion of the Investigator).
Carboplatin
Carboplatin was administered intravenously as per standard of care.
Paclitaxel
Paclitaxel was administered intravenously as per standard of care.
Bevacizumab
Bevacizumab was administrated as indicated for standard of care.
Cisplatin
Cisplatin was administered intravenously as per standard of care.
Radiotherapy
Participants received radiotherapy as per standard of care.
Augusta University - formerly Georgia Regents University, Augusta
University of Cincinnati Physicians Group, LLC - Pharmatech Oncology, Inc, Cincinnati
UT Southwestern Medical Center, Dallas
Comprehensive Cancer Centers of Nevada, Henderson
Stanford Health Care Hospital & Clinics, Stanford
National Cancer Center Hospital, Chūōku
Saitama Medical University International Medical Center, Hidaka-shi
Cancer Institute Hospital of JFCR, Kōtoku
Osaka International Cancer Institute, Osaka
Shizuoka Cancer Center, Sunto-gun
Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia, Barcelona
Hospital Universitari Vall d'Hebron - Dept of Oncology, Barcelona
ICO l´Hospitalet - Hospital Duran i Reynals - Servicio de Oncologia, Barcelona
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY